

## CLAIMS

1. A method for determining toxicity to the heart of an anthracycline-type anticancer chemotherapeutic agent, which comprises detecting human H-FABP in the blood separated from  
5 human.
2. The method of claim 1, wherein the detection of human H-FABP is performed by an immunochemical method using an antibody that recognizes human H-FABP.  
10
3. The method of claim 2, wherein the immunochemical method is an enzyme immunochemical method, a latex agglutination assay or an immunochromatographic assay.
- 15 4. The method of claim 2, wherein the antibody is a monoclonal antibody.
5. The method of claim 1, wherein the anthracycline-type anticancer chemotherapeutic agent is adriamycin or daunorubicin  
20 hydrochloride.
6. A reagent for determining toxicity to the heart of an anthracycline-type anticancer chemotherapeutic agent, which is used for performing the method of any of claims 1 to 5.  
25
7. A reagent for determining toxicity to the heart of an anthracycline-type anticancer chemotherapeutic agent, which comprises an antibody that recognizes human H-FABP.
- 30 8. The reagent of claim 7, wherein the antibody is a monoclonal antibody.
9. The reagent of claim 7, wherein the anthracycline-type anticancer chemotherapeutic agent is adriamycin or daunorubicin

hydrochloride.

10. A commercial package comprising the reagent of any of  
claims 7 to 9, and a written matter associated therewith, the  
5 written matter stating that said reagent can or should be used  
for determining toxicity to the heart of an anthracycline-type  
anticancer chemotherapeutic agent.

11. A kit for determining toxicity to the heart of an  
10 anthracycline-type anticancer chemotherapeutic agent, which  
comprises an antibody that recognizes human H-FABP.

12. The kit of claim 11, wherein the antibody is a monoclonal  
antibody.

15

13. The kit of claim 11, wherein the anthracycline-type  
anticancer chemotherapeutic agent is adriamycin or daunorubicin  
hydrochloride.

20 14. Use of an antibody that recognizes human H-FABP for  
determining toxicity to the heart of an anthracycline-type  
anticancer chemotherapeutic agent.

15. The use of claim 14, which comprises detecting human H-FABP  
25 in the blood separated from human.

16. The use of claim 15, wherein the detection of human H-FABP  
is performed by an enzyme immunochemical method, a latex  
agglutination assay or an immunochromatographic assay.

30

17. The use of claim 14, wherein the antibody is a monoclonal  
antibody.

18. The use of claim 14, wherein the anthracycline-type

anticancer chemotherapeutic agent is adriamycin or daunorubicin hydrochloride.